Mizuho Lowers Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $1.50

Adaptimmune Therapeutics (NASDAQ:ADAP) had its target price trimmed by Mizuho from $3.00 to $1.50 in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock.

Other research analysts have also recently issued research reports about the stock. HC Wainwright dropped their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a report on Thursday, November 14th. Guggenheim dropped their price objective on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Finally, StockNews.com cut shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $2.79.

Adaptimmune Therapeutics Price Performance

Adaptimmune Therapeutics stock opened at $0.73 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. Adaptimmune Therapeutics has a 52 week low of $0.42 and a 52 week high of $2.05. The stock has a market capitalization of $185.51 million, a P/E ratio of -3.18 and a beta of 2.26. The stock has a fifty day moving average of $0.82 and a 200-day moving average of $1.01.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several hedge funds have recently added to or reduced their stakes in ADAP. Fullcircle Wealth LLC acquired a new position in Adaptimmune Therapeutics in the 3rd quarter valued at approximately $33,000. Vontobel Holding Ltd. grew its stake in shares of Adaptimmune Therapeutics by 230.8% in the third quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 30,000 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Adaptimmune Therapeutics in the third quarter valued at $95,000. Virtu Financial LLC raised its position in Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 21,769 shares during the last quarter. Finally, Jane Street Group LLC grew its position in shares of Adaptimmune Therapeutics by 130.4% in the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 98,581 shares during the last quarter. 31.37% of the stock is currently owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.